NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Summary

The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.

Timeline

Start

2020-02-19

Primary completion

2026-06-28

Completion

2026-07-01

Drugs

Indications